港股“科技双雄”接力上攻，港股通创新药ETF（520880）涨近2%强势4连阳，机构：中国科技资产风险回报比突出

Group 1 - The Hong Kong stock market experienced a rebound, with the Hang Seng Index reaching a nearly four-month high before closing slightly down [1][3] - The technology sector, particularly innovative drugs and internet leaders, showed strong performance, with the Hong Kong Internet ETF (513770) initially rising by 2.7% before closing up 0.72% [1][3] - The innovative drug sector is benefiting from favorable domestic policies and a surge in global market demand, with expectations for significant growth in 2025 as companies transition from generic to innovative drugs [3][4] Group 2 - The Hang Seng Innovation Drug ETF (520880) has shown a strong performance, with a cumulative increase of 58.95% [5] - The ETF focuses on the innovative drug industry, with the top ten constituent stocks accounting for 75.85% of its weight, indicating a significant concentration in leading companies [4] - The Hong Kong Internet ETF (513770) has a strong liquidity profile, with an average daily trading volume of 594 million yuan, supporting T+0 trading without QDII quota restrictions [9] Group 3 - The recent U.S. economic data, showing a 0.2% increase in the core CPI for June, has led to speculation about potential interest rate cuts by the Federal Reserve, which could benefit the Hong Kong market [3][4] - The ongoing U.S.-China tariff negotiations are perceived positively, with expectations of upcoming talks, which may further support market sentiment [4] - The overall valuation of Hong Kong stocks remains low historically, enhancing the risk-return profile for foreign investments in Chinese technology assets [4]